Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Analysis of Antitumor B in Oral Cancer
NCT03459729Phase 1Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Antitumor B in oral cavity squamous cell carcinoma (OCSCC), sponsored by Medical College of Wisconsin. Primary endpoints: Area Under the Curve (AUC) for Matrine in Saliva at Day 1, Area Under the Curve for Matrine in Plasma at Day 1 and 6 more. Started Aug 2021; status: completed.
02
Drugs
Antitumor B
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT03459729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459729.